Who We Are

PhD researchers, clinical pathologists, and diagnostics industry leaders operating at the intersection of science, technology, and business strategy.

Whether you manage a start-up with a novel marker, a traditional IVD company competing for market share, an established company with a new research platform, a pharmaceutical company struggling with companion diagnostic commercialization, or a clinical laboratory exploring expansion of testing services, the Health Advances Diagnostics and Life Science Tools team can help you realize your business’ potential.

How We Help Your Business

Pragmatic strategies based on deep industry insight.

Featured Areas

Life Science Tools
Lab and Point of Care Product Strategy
Hospital Lab Strategy
Personalized Medicine


Donna Hochberg: “One of the biggest challenges to commercializing a new research or diagnostic technology is clearly identifying your true target customers. We’ve had a number of recent successes assisting our clients in creatively segmenting customers into easily identifiable and targetable groups, deploying sales reps to the most productive prospects and thereby enabling more effective launch.”

Mark Speers: “It is very fulfilling to be involved with clients periodically as they advance their technologies and see opportunities to refresh their competitive and customer intelligence. Over the course of several years, we assisted a client in the decision to invest in a nascent technology, develop the market to adopt the new technology, and prepare for an exit. The company was recently purchased by a large, established IVD player for several hundred million dollars.”

Gary Gustavsen: “A key focus area for the practice recently has been global commercialization of companion diagnostics. We recently completed a large project for a major biopharma that further validated the need for a globally-orchestrated, but locally-tailored strategy. The barriers to CDx adoption across markets are so unique; every country needs its own set of tactics.”

Case Studies

Diagnostic Assay Global Launch
Drug Discovery Strategy
Test Menu Optimization

View additional diagnostics and life science tools examples here.

Practice Leaders

Contact the Diagnostics and Life Science Tools Team

Related Areas

Due Diligence
Reimbursement and Pricing Strategy
Technology Commercialization

Recent News, Events & Publications


Health Advances Adds to Leadership Team

Today, Health Advances promoted Gary Gustavsen, Wyatt Gotbetter, and Andrew Matzkin to the position of Partner to recognize their outstanding contributions. All three Partners are highly regarded in the life sciences industry for their thought leadership, passion for improving the lives of patients, and commitment to client service. Equally important, all three are highly regarded as role models and leaders in the firm, investing heavily in mentoring staff and reinforcing the firm’s culture. This move positions Health Advances for continued growth by bringing the Partner group to a total of 11 professionals.

Gary Gustavsen leads the Personalized Medicine Practice at Health Advances, where his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, and business development opportunities for both diagnostic and therapeutic clients. Gary has been with Health Advances for nearly 12 years, rapidly advancing through the ranks from the entry level Analyst position. Prior to joining Health Advances, Gary worked at Brookhaven National Lab, Becton Dickinson, and OSI Pharmaceuticals. Gary received his BSE degree in Biomedical Engineering from Duke University and his MS degree in Biomedical Engineering from Stony Brook University.
Wyatt Gotbetter, with over 2 decades of experience in the life sciences industry, helps lead the Biopharma Practice and focuses on commercial growth and business development strategies for therapeutics companies. Wyatt joined Health Advances over 3 years ago after working at Boston Consulting Group (BCG), Biogen, and Boston Scientific in strategy, product and portfolio management and new product commercialization. He earned his BS degree in Economics & Policy Analysis and an MPA degree, including a certificate from the Sloan Graduate Program in Health Services Management, at Cornell University.

Andrew Matzkin has 15 years of experience as a strategy consultant in healthcare, including 8 years at Health Advances. He leads the Digital Health and Health IT Practice, working closely with companies and investors in digital health, health IT, and the life sciences to develop strategies for development and commercialization of digital solutions. His areas of emphasis include connected devices and diagnostics, patient monitoring, digital disease management, real world data, and big data analytics across a wide range of technologies and therapeutic areas. Prior to Health Advances, Andrew was a Consultant at Bain & Company and also worked at Novartis in the global cardiovascular-metabolic franchise. Andrew earned his BA degree, Phi Beta Kappa, from Yale University and an MBA from Harvard Business School, where he was honored as a Baker Scholar.

“Health Advances approaches a problem like they’re part of your company and have a real stake in the game. We were a fledgling startup with a novel diagnostic capability and we needed to understand the markets where we could make a big difference in health care. Health Advances looked at the entire landscape of clinical diagnostics and directed us to a market that became a foundation for our company. We’ve now raised over $90 million and grown from 8 to 60 people.”

John McDonough
Chief Executive Officer
T2 Biosystems